预测心力衰竭患者支持左心室辅助装置的败血症:VE-Cadherin和ADAM10的作用
Shiyi Li1,2, Iván Murrieta-Álvarez2, Ismael Garcia2
1Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China.
International journal of molecular sciences
|January 28, 2026
概括
血管内皮卡德林 (VE-Cadherin) 和ADAM10的血水平可以预测左心室辅助器件 (LVAD) 的患者的败血症. 这些生物标志物的较高水平表明LVAD患者的败血症风险增加.
科学领域:
- 心血管医学 心血管医学
- 生物标志物发现发现
- 关键的护理关键的护理
背景情况:
- 血管过性增加了左心室辅助器件 (LVAD) 患者的败血症易感性.
- 血管内皮卡德林 (VE-Cadherin) 是一个关键的内皮粘附分子,由ADAM10分裂.
- 预测LVAD患者的败血症对于改善结果至关重要.
研究的目的:
- 评估VE-Cadherin和ADAM10作为LVAD患者败血症的预测因素.
- 评估VE-Cadherin和ADAM10对败血症的联合预测性能.
- 调查VE-Cadherin,ADAM10和败血症发展之间的关系.
主要方法:
- 有望招募50名正在接受LVAD治疗的晚期心力衰竭患者.
- 收集连续血液样本 (基线和手术后的1-4周).
- 使用验证的测定方法测量血VE-卡德林和ADAM10水平.
主要成果:
- 败血症发生在18.0%的患者 (50人中有9人) 中.
- 与非败血症患者相比,败血症患者的血VE-Cadherin和ADAM10水平显著升高.
- 单独使用VE-Cadherin,预测性表现良好 (AUC从0.69到0.81不等).
- 纳入ADAM10显著提高了预测模型的性能.
结论:
- 血VE-Cadherin是一种有价值的生物标志物,用于预测LVAD患者的败血症.
- 将VE-Cadherin与ADAM10水平相结合,进一步提高了败血症预测的准确性.
- 这些发现可能有助于早期检测和管理LVAD接受者的败血症.
相关概念视频
01:29Heart Failure II: Pathophysiology
872
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
872
01:17Pathophysiology of Heart Failure
3.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
01:27Heart Failure I: Introduction
847
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
847
01:22Heart Failure VI: Adjunct Therapies
314
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314
01:22Heart Failure Drugs: Diuretics
948
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
948
01:30Heart Failure V: Medical Management
272
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
272